A phase II study of rituximab combined with pirarubicincyclophosphamide, vincristine and prednisolone regimen as first-line therapy for patients with indolent B-cell lymphoma

Hisashi Tsurumi, Takeshi Hara, Naoe Goto, Jun Ichi Kitagawa, Nobuhiro Kanemura, Takeshi Yoshikawa, Senji Kasahara, Hideko Goto, Kenji Fukuno, Toshiki Yamada, Michio Sawada, Masahito Shimizu, Takeshi Takahashi, Tsuyoshi Takami, Hisataka Moriwaki

研究成果: Article査読

3 被引用数 (Scopus)

抄録

The anthracycline drug pirarubicin (tetrahydropyranyl-adriamycin [THP]) apparently has been reported to show fewer cardiotoxic effects than doxorubicin. We have previously described the effectiveness of the R-THP-COP regimen comprising rituximab, cyclophosphamide, pirarubicin, vincristine and prednisolone in patients with diffuse large B-cell lymphoma. We conducted a phase II study to determine the effectiveness of a regimen incorporating rituximab (R-THP-COP) for patients with previously untreated advanced-stage indolent CD20-positive B-cell lymphoma according to the Working Formulation and World Health Organization classification. Four to six courses of the regimen were administered every 3 weeks in 50 patients. The complete remission rate was 57%, while the 3-year overall survival rate was 92%. Regimen-related death was not observed. The R-THP-COP regimen appears very effective for patients with previously untreated advanced-stage indolent CD20-positive B-cell lymphoma. The present results indicate the need for randomized trials of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) and R-THP-COP among patients with CD20-positive indolent lymphoma.

本文言語English
ページ(範囲)247-253
ページ数7
ジャーナルLeukemia and Lymphoma
53
2
DOI
出版ステータスPublished - 02-2012
外部発表はい

All Science Journal Classification (ASJC) codes

  • 血液学
  • 腫瘍学
  • 癌研究

フィンガープリント

「A phase II study of rituximab combined with pirarubicincyclophosphamide, vincristine and prednisolone regimen as first-line therapy for patients with indolent B-cell lymphoma」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル